Banner

Improved form of brimonidine has fewer contraindications

Article

Brimonidine tartrate 0.15% (Alphagan P, Allergan) is a "new and improved" version of brimonidine 0.2% (Alphagan, Allergan). It continues to have an efficacy profile similar to the one ophthalmologists have grown used to with brimonidine 0.2%.

Related Videos
Related Content

Eyecbetter announces Amy Dixon, PLY (Paralympian), as new Director of Patient Advocacy

September 23rd 2023

EyePod: Week in Review - September 17, 2023

September 23rd 2023

Foundation Fighting Blindness awards $900,000 to MitoChem Therapeutics to study target and mechanism of action in retinal degeneration disease

September 22nd 2023

EyePod: Week in Review - September 10, 2023

September 16th 2023

Study: Researchers find new mechanisms that cause blindness, opening the door to future treatments

September 22nd 2023

Balancing Motherhood and Medicine: Navigating Maternity in Ophthalmology

September 22nd 2023

Eyecbetter announces Amy Dixon, PLY (Paralympian), as new Director of Patient Advocacy

September 23rd 2023

EyePod: Week in Review - September 17, 2023

September 23rd 2023

Foundation Fighting Blindness awards $900,000 to MitoChem Therapeutics to study target and mechanism of action in retinal degeneration disease

September 22nd 2023

EyePod: Week in Review - September 10, 2023

September 16th 2023

Study: Researchers find new mechanisms that cause blindness, opening the door to future treatments

September 22nd 2023

Balancing Motherhood and Medicine: Navigating Maternity in Ophthalmology

September 22nd 2023

Eyecbetter announces Amy Dixon, PLY (Paralympian), as new Director of Patient Advocacy

September 23rd 2023

EyePod: Week in Review - September 17, 2023

September 23rd 2023

Foundation Fighting Blindness awards $900,000 to MitoChem Therapeutics to study target and mechanism of action in retinal degeneration disease

September 22nd 2023

EyePod: Week in Review - September 10, 2023

September 16th 2023

Study: Researchers find new mechanisms that cause blindness, opening the door to future treatments

September 22nd 2023

Balancing Motherhood and Medicine: Navigating Maternity in Ophthalmology

September 22nd 2023
© 2023 MJH Life Sciences

All rights reserved.